Praxis Precision Medicines (PRAX) said late Tuesday it priced an underwritten public offering of about 2.2 million of its common shares at $260 apiece for expected gross proceeds of roughly $575 million.
The company has provided a 30-day option to the underwriters to buy up to its 331,800 additional common shares, it said.
Praxis said it intends to close the offering around Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.